Bayer and Iambic Collaborate to Advance Drug Discovery with AI

▤ Summary

Bayer and Iambic have launched a drug discovery collaboration centered on AI-driven small molecule research. Bayer will use Iambic’s platform, including Enchant and NeuralPLexer, to find new entry points for hard-to-drug targets and speed up early discovery. The agreement includes an upfront payment plus milestone and royalty economics for Iambic. The deal highlights how pharma buyers are adopting AI software to improve pipeline quality, reduce discovery timelines, and increase R&D productivity.

▦ Linked Companies